The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
Testing will be performed by Biocept in the US, and HarlePhil Ventures will sell, market, distribute, and collect reimbursements in the Philippines.
The firm's second quarter revenues grew more than seven times year over year based on a large increase in billable samples.
The firm's total revenues increased 47 percent to $221,369 for the quarter, mainly driven by continued expansion of commercial liquid biopsy test volumes.
The company said that it intends to use the proceeds of the stock and warrant offering for working capital, as well as general corporate purposes.
Biocept hopes data from the study will support the clinical utility of its liquid biopsy test to detect drug resistance mutations in NSCLC.
Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.
Progenetics will market and distribute Biocept's complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.
The firm saw its Q4 revenues rise to $218,000 year over year, mainly due to expansion of its commercial liquid biopsy testing business.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.